Hoffmeister Torben, Schwenke Dirk, Krug Oliver, Wachsmuth Nadine, Geyer Hans, Thevis Mario, Byrnes William C, Schmidt Walter F J
Department of Sports Medicine and Sports Physiology, University of Bayreuth, Bayreuth, Germany.
Institute of Doping Analysis und Sports Biochemistry, University of Dresden, Dresden, Germany.
Front Physiol. 2018 Sep 19;9:1289. doi: 10.3389/fphys.2018.01289. eCollection 2018.
Cobalt ions (Co) stabilize HIFα and increase endogenous erythropoietin (EPO) production creating the possibility that Co supplements (CoSupp) may be used as performance enhancing substances. The aim of this study was to determine the effects of a small oral dosage of CoSupp on hemoglobin mass (Hbmass) and performance with the objective of providing the basis for establishing upper threshold limits of urine [Co] to detect CoSupp misuse in sport. Twenty-four male subjects participated in a double-blind placebo-controlled study. Sixteen received an oral dose of 5 mg of ionized Co per day for 3 weeks, and eight served as controls. Blood and urine samples were taken before the study, during the study and up to 3 weeks after CoSupp. Hbmass was determined by the CO-rebreathing method at regular time intervals, and VO was determined before and after the CoSupp administration period. In the Co group, Hbmass increased by 2.0 ± 2.1% ( < 0.001) while all the other analyzed hematological parameters did not show significant interactions of time and treatment. Hemoglobin concentration ([Hb]) and hematocrit (Hct) tended to increase ( = 0.16, = 0.1) and also [EPO] showed a similar trend (baseline: 9.5 ± 3.0, after 2 weeks: 12.4 ± 5.2 mU/ml). While mean VO did not change, there was a trend for a positive relationship between changes in Hbmass and changes in VO immediately after CoSupp ( = 0.40, = 0.11). Urine [Co] increased from 0.4 ± 0.3 to 471.4 ± 384.1 ng/ml ( < 0.01) and remained significantly elevated until 2 weeks after cessation. An oral Co dosage of 5 mg/day for 3 weeks effectively increases Hbmass with a tendency to increase hemoglobin concentration ([Hb]) and hematocrit (Hct). Because urine Co concentration remains increased for 2 weeks after cessation, upper limit threshold values for monitoring CoSupp can be established.
钴离子(Co)可稳定低氧诱导因子α(HIFα)并增加内源性促红细胞生成素(EPO)的产生,这使得补充钴(CoSupp)有可能被用作提高运动成绩的物质。本研究的目的是确定小剂量口服CoSupp对血红蛋白量(Hbmass)和运动表现的影响,以便为确定尿液中[Co]的上限阈值提供依据,从而检测体育运动中CoSupp的滥用情况。24名男性受试者参与了一项双盲安慰剂对照研究。16人每天口服5毫克离子化钴,持续3周,8人作为对照。在研究前、研究期间以及CoSupp停用后长达3周内采集血液和尿液样本。定期通过一氧化碳再呼吸法测定Hbmass,并在CoSupp给药期前后测定VO。在Co组中,Hbmass增加了2.0±2.1%(P<0.001),而其他所有分析的血液学参数均未显示出时间和治疗的显著相互作用。血红蛋白浓度([Hb])和血细胞比容(Hct)有增加趋势(P=0.16,P=0.1),[EPO]也呈现类似趋势(基线:9.5±3.0,2周后:12.4±5.2 mU/ml)。虽然平均VO没有变化,但CoSupp后立即出现Hbmass变化与VO变化呈正相关趋势(P=0.40,P=0.11)。尿液[Co]从0.4±0.3增加到471.4±384.1 ng/ml(P<0.01),并在停药后2周内一直显著升高。每天口服5毫克Co,持续3周可有效增加Hbmass,同时有增加血红蛋白浓度([Hb])和血细胞比容(Hct)的趋势。由于停药后2周内尿液Co浓度持续升高,因此可以确定监测CoSupp的上限阈值。